Loading…

Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke

Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between M...

Full description

Saved in:
Bibliographic Details
Published in:Journal of stroke and cerebrovascular diseases 2017-04, Vol.26 (4), p.733-740
Main Authors: Abdelnaseer, Maged M., MD, Elfauomy, Nervana M., MD, Esmail, Eman H., MD, Kamal, Manal M., MD, Elsawy, Enji H., MSc
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83
cites cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83
container_end_page 740
container_issue 4
container_start_page 733
container_title Journal of stroke and cerebrovascular diseases
container_volume 26
creator Abdelnaseer, Maged M., MD
Elfauomy, Nervana M., MD
Esmail, Eman H., MD
Kamal, Manal M., MD
Elsawy, Enji H., MSc
description Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.
doi_str_mv 10.1016/j.jstrokecerebrovasdis.2016.09.043
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1856867807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1052305716303743</els_id><sourcerecordid>1856867807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</originalsourceid><addsrcrecordid>eNqVkU1v1DAQhi1URD_gL6AcUaUETxwn9gW1XZVSaSskCmfLmUyE02zc2smK_fd42cIBceE0lubVM-NnGDsHXgCH-v1QDHEO_oGQArXBb23sXCzK1Cu4LnglXrATkKLMlQQ4Sm8uy1xw2Ryz0xgHzgGkkq_Ycal4LZoGTtjFnZ2D-5Hd0WzH0T8GP5ObbKRcZ3bqsi-Efkthl_k-u8Rlpuw24nfaOMzuf-3ymr3s7RjpzXM9Y98-Xn9dfcrXn29uV5frHCup57zqmrYHoh4qLStFnYZGYqulEqCVQC1LTqKuS12rXgnCFrCzirdSqBJRiTP27sBNKz4tFGezcRFpHO1EfokGlKxV3SjepOjVIYrBxxioN4_BbWzYGeBmb9IM5l8mzd6k4dokkwny9nne0m6o-4P4rS4F1ocApV9vHQUT0dGE1LlAOJvOu_-b9-EvHI5ucmjHB9pRHPwSpuTXgIml4eZ-f9v9aaEWXDQJ8BOrvKdI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856867807</pqid></control><display><type>article</type><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</creator><creatorcontrib>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</creatorcontrib><description>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2016.09.043</identifier><identifier>PMID: 28063771</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Brain Ischemia - complications ; Cardiovascular ; Case-Control Studies ; Female ; Humans ; Male ; Matrix metalloproteinase ; Matrix Metalloproteinase 9 - blood ; Middle Aged ; modified Rankin Scale ; Neurology ; NIHSS ; outcome ; predictor ; recovery ; Recovery of Function - physiology ; Severity of Illness Index ; Statistics as Topic ; stroke ; Stroke - blood ; Stroke - etiology</subject><ispartof>Journal of stroke and cerebrovascular diseases, 2017-04, Vol.26 (4), p.733-740</ispartof><rights>National Stroke Association</rights><rights>2017 National Stroke Association</rights><rights>Copyright © 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</citedby><cites>FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28063771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelnaseer, Maged M., MD</creatorcontrib><creatorcontrib>Elfauomy, Nervana M., MD</creatorcontrib><creatorcontrib>Esmail, Eman H., MD</creatorcontrib><creatorcontrib>Kamal, Manal M., MD</creatorcontrib><creatorcontrib>Elsawy, Enji H., MSc</creatorcontrib><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</description><subject>Aged</subject><subject>Brain Ischemia - complications</subject><subject>Cardiovascular</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Middle Aged</subject><subject>modified Rankin Scale</subject><subject>Neurology</subject><subject>NIHSS</subject><subject>outcome</subject><subject>predictor</subject><subject>recovery</subject><subject>Recovery of Function - physiology</subject><subject>Severity of Illness Index</subject><subject>Statistics as Topic</subject><subject>stroke</subject><subject>Stroke - blood</subject><subject>Stroke - etiology</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqVkU1v1DAQhi1URD_gL6AcUaUETxwn9gW1XZVSaSskCmfLmUyE02zc2smK_fd42cIBceE0lubVM-NnGDsHXgCH-v1QDHEO_oGQArXBb23sXCzK1Cu4LnglXrATkKLMlQQ4Sm8uy1xw2Ryz0xgHzgGkkq_Ycal4LZoGTtjFnZ2D-5Hd0WzH0T8GP5ObbKRcZ3bqsi-Efkthl_k-u8Rlpuw24nfaOMzuf-3ymr3s7RjpzXM9Y98-Xn9dfcrXn29uV5frHCup57zqmrYHoh4qLStFnYZGYqulEqCVQC1LTqKuS12rXgnCFrCzirdSqBJRiTP27sBNKz4tFGezcRFpHO1EfokGlKxV3SjepOjVIYrBxxioN4_BbWzYGeBmb9IM5l8mzd6k4dokkwny9nne0m6o-4P4rS4F1ocApV9vHQUT0dGE1LlAOJvOu_-b9-EvHI5ucmjHB9pRHPwSpuTXgIml4eZ-f9v9aaEWXDQJ8BOrvKdI</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Abdelnaseer, Maged M., MD</creator><creator>Elfauomy, Nervana M., MD</creator><creator>Esmail, Eman H., MD</creator><creator>Kamal, Manal M., MD</creator><creator>Elsawy, Enji H., MSc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</title><author>Abdelnaseer, Maged M., MD ; Elfauomy, Nervana M., MD ; Esmail, Eman H., MD ; Kamal, Manal M., MD ; Elsawy, Enji H., MSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Brain Ischemia - complications</topic><topic>Cardiovascular</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Middle Aged</topic><topic>modified Rankin Scale</topic><topic>Neurology</topic><topic>NIHSS</topic><topic>outcome</topic><topic>predictor</topic><topic>recovery</topic><topic>Recovery of Function - physiology</topic><topic>Severity of Illness Index</topic><topic>Statistics as Topic</topic><topic>stroke</topic><topic>Stroke - blood</topic><topic>Stroke - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelnaseer, Maged M., MD</creatorcontrib><creatorcontrib>Elfauomy, Nervana M., MD</creatorcontrib><creatorcontrib>Esmail, Eman H., MD</creatorcontrib><creatorcontrib>Kamal, Manal M., MD</creatorcontrib><creatorcontrib>Elsawy, Enji H., MSc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelnaseer, Maged M., MD</au><au>Elfauomy, Nervana M., MD</au><au>Esmail, Eman H., MD</au><au>Kamal, Manal M., MD</au><au>Elsawy, Enji H., MSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>26</volume><issue>4</issue><spage>733</spage><epage>740</epage><pages>733-740</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>Background Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9—after the acute stage—and clinical recovery. Objective The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery. Methods The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group. Results The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery. Conclusion Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28063771</pmid><doi>10.1016/j.jstrokecerebrovasdis.2016.09.043</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1052-3057
ispartof Journal of stroke and cerebrovascular diseases, 2017-04, Vol.26 (4), p.733-740
issn 1052-3057
1532-8511
language eng
recordid cdi_proquest_miscellaneous_1856867807
source ScienceDirect Freedom Collection 2022-2024
subjects Aged
Brain Ischemia - complications
Cardiovascular
Case-Control Studies
Female
Humans
Male
Matrix metalloproteinase
Matrix Metalloproteinase 9 - blood
Middle Aged
modified Rankin Scale
Neurology
NIHSS
outcome
predictor
recovery
Recovery of Function - physiology
Severity of Illness Index
Statistics as Topic
stroke
Stroke - blood
Stroke - etiology
title Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A18%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20Metalloproteinase-9%20and%20Recovery%20of%20Acute%20Ischemic%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Abdelnaseer,%20Maged%20M.,%20MD&rft.date=2017-04-01&rft.volume=26&rft.issue=4&rft.spage=733&rft.epage=740&rft.pages=733-740&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2016.09.043&rft_dat=%3Cproquest_cross%3E1856867807%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-4d7bf1eef149548ed9175cb95831983c9520e3662968f83ecb1cda80b5382cc83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1856867807&rft_id=info:pmid/28063771&rfr_iscdi=true